Last reviewed · How we verify
Stiptanon — Competitive Intelligence Brief
unknown
estriol succinate
Corticosteroid-binding globulin, Olfactory receptor 51E2, Alpha-synuclein
Other
Live · refreshed every 30 min
Target snapshot
Stiptanon (estriol succinate). Stiptanon works by binding to estrogen receptors, specifically the beta subtype, to exert its effects.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Stiptanon TARGET | estriol succinate | unknown | estriol succinate | Corticosteroid-binding globulin, Olfactory receptor 51E2, Alpha-synuclein | ||
| Destriol | ESTRIOL | marketed | estriol | Corticosteroid-binding globulin, Olfactory receptor 51E2, Alpha-synuclein | 2000-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (estriol succinate class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Stiptanon CI watch — RSS
- Stiptanon CI watch — Atom
- Stiptanon CI watch — JSON
- Stiptanon alone — RSS
- Whole estriol succinate class — RSS
Cite this brief
Drug Landscape (2026). Stiptanon — Competitive Intelligence Brief. https://druglandscape.com/ci/estriol-succinate. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing